• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

by Syed Hamza Sohail 07/28/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).

– This agreement marks NeuraLight’s first clinical trial and comes on the heels of NeuraLight’s $25M Series A raise, less than six months after launching the company out of stealth. 

Digitizing Neurological Evaluation and Care

NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Using their AI-driven platform to integrate multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders, NeuraLight is revolutionizing patient care.

NeuraLight’s platform, which uses proprietary computer vision and deep learning algorithms to extract over 100 occulometic markers from facial videos captured with a standard webcam, will be used to evaluate ALS patients in a study parallel to NeuroSense’s Phase IIb PARADIGM trial. PARADIGM is a double-blind, placebo-controlled study evaluating the efficacy of NeuroSense’s lead combination drug candidate, PrimeC, in the treatment of ALS. The NeuroSense-NeuraLight collaboration entails sharing and tracking patient data to advance the identification and use of ALS digital biomarkers.  

“There is compelling value in the use of precise biomarkers to diagnose and track the progression of neurodegenerative diseases. We are very pleased to work with the stellar team at NeuraLight who are pioneering the development of digital oculometric biomarkers. This is a great complement to our ongoing collaboration with Massachusetts General Hospital on biological markers of ALS,” said NeuroSense CEO Alon Ben-Noon. “We believe these tools have the potential to enable patient stratification and increase likelihood of success in a pivotal trial. This is a first step in what we envision as a long-term collaboration with NeuraLight in ALS as well as future studies we plan for Alzheimer’s disease and Parkinson’s disease.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, algorithms, Alzheimer’s disease, Biomarkers, Clinical Trial, Deep Learning, Digital Biomarkers, neurodegenerative diseases, Patient Care, patient stratification

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

HLTH 2025 Coverage

HLTH 2025 Day 1 Summary & Insights: AMA Launches AI Governance Center, Google Cloud, Microsoft, ChatGPT for Medicine

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Cleveland Clinic and Khosla Ventures Form Strategic Alliance to Accelerate Healthcare Innovation

Northwell Health Selects to Deploy Abridge’s Ambient AI Across 28 Hospitals

Northwell Health to Deploy Abridge’s Ambient AI Across 28 Hospitals

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |